IMV Inc. annonce le prix de son placement public
March 01, 2019 11:05 ET
|
IMV Inc.
DARTMOUTH, Nouvelle-Écosse, 01 mars 2019 (GLOBE NEWSWIRE) -- IMV Inc. (« IMV » ou la « société ») (NASDAQ : IMV; TSX : IMV), société de recherche clinique en immuno‑oncologie, annonce...
IMV Inc. Announces Pricing of Public Offering
March 01, 2019 10:02 ET
|
IMV Inc.
DARTHMOUTH, Nova Scotia, March 01, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing...
IMV Inc. dépose un supplément de prospectus provisoire dans le cadre d’un projet d’appel public à l’épargne visant des actions ordinaires
February 28, 2019 16:53 ET
|
IMV Inc.
DARTHMOUTH, Nouvelle-Écosse, 28 févr. 2019 (GLOBE NEWSWIRE) -- IMV Inc. (« IMV » ou la « société ») (NASDAQ : IMV; TSX : IMV), société de recherche clinique en immuno‑oncologie, dépose...
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
February 28, 2019 16:51 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has today filed a preliminary...
IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
January 29, 2019 07:05 ET
|
IMV Inc.
DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment FDA provided guidance for future registration trial design and for a potential shorter...
IMV to Present at 2019 BIO CEO & Investor Conference
January 28, 2019 16:35 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and...
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
January 17, 2019 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in...
IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
December 13, 2018 04:05 ET
|
IMV Inc.
73% of tumor regressions and 80% of clinical responses were observed in a subpopulation defined by a clinical biomarker based on Baseline Tumor Burden All durable clinical responses continued beyond...
IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
December 10, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Dec. 10, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that investigators will present data via a...
IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications
December 05, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Dec. 05, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Marc Jasmin has joined the Company in...